Biologics, Small Molecules and More in Inflammatory Bowel Disease: The Present and the Future
Open Access
- 14 March 2024
- journal article
- review article
- Published by MDPI AG in Future Pharmacology
- Vol. 4 (1) , 279-316
Abstract
Inflammatory bowel disease (IBD) is a group of heterogeneous chronic inflammatory diseases of the gut presenting with intestinal and extraintestinal manifestations. Most cases fit in predominantly two types, namely, ulcerative colitis and Crohn’s disease. The incidence of IBD has been increasing steadily in the past three decades. Focused research has resulted in many therapeutic options. Biologics (derived from humans or animals) and small molecules have emerged as the cornerstone in the management of IBD and have become widely available. Currently, monoclonal antibodies against tumor necrosis factor-alpha (infliximab, adalimumab, certolizumab, and golimumab), integrins (vedolizumab and natalizumab), and interleukin (IL)-12 and IL-23 antagonists (ustekinumab), along with small molecules (tofacitinib), are approved for use. This article summarizes various aspects of these drugs, like clinical pharmacology, indications for use in IBD, safety in pregnancy and lactation, and the adverse effects profile based on the studies leading to their approval. This review also focuses on the recent advances and future perspectives specific to biologics in IBD.Keywords
This publication has 182 references indexed in Scilit:
- Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case SeriesDigestive Diseases and Sciences, 2022
- Filgotinib in Rheumatoid Arthritis: A Profile of Its UseClinical Drug Investigation, 2021
- A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseasesJGH Open, 2018
- A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabClinical Pharmacokinetics, 2017
- Efficacy and safety of golimumab 52-week maintenance therapy in Japanese patients with moderate to severely active ulcerative colitis: a phase 3, double-blind, randomized, placebo-controlled study-(PURSUIT-J study)Journal of Gastroenterology, 2017
- Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and PsoriasisDrug Safety, 2016
- Targeting Leukocyte Trafficking for the Treatment of Inflammatory Bowel DiseaseClinical Pharmacology & Therapeutics, 2014
- Vedolizumab for induction and maintenance of remission in ulcerative colitisCochrane Database of Systematic Reviews, 2014
- Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter studyInflammatory Bowel Diseases, 2012
- Efficacy of infliximab in refractory pouchitis and Crohnʼs disease-related complications of the pouch: A Belgian case seriesInflammatory Bowel Diseases, 2010